Skip to main content
Premium Trial:

Request an Annual Quote

Dow Extends Genomatica Agreement

NEW YORK, May 3 (GenomeWeb News) - Genomatica last week said that it has extended a research agreement with the Dow Chemical Company that began in 2002, after successfully achieving "a series of scientific milestones."

 

Under the terms of the extended agreement, Dow has licensed Genomatica's SimPheny modeling and simulation technology, which it will use to improve recombinant protein expression from specially designed strains of Pseudomonas fluorescens. Scientists at Genomatica will collaborate with Dow researchers on the project.

 

Financial terms of the expanded agreement were not disclosed.

 

 

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.